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Abstract
Aim
Aim of this study was to investigate the potential of 18F-FDG PET, diffusion weighted imag-
ing (DWI) and susceptibility-weighted (T2*) MRI to predict response to systemic treatment
in patients with colorectal liver metastases. The predictive values of pretreatment measure-
ments and of early changes one week after start of therapy, were evaluated.
Methods
Imaging was performed prior to and one week after start of first line chemotherapy in 39 pa-
tients with colorectal liver metastases. 18F-FDG PET scans were performed on a PET/CT
scanner and DWI and T2* were performed on a 1.5T MR scanner. The maximum standard-
ized uptake values (SUV), total lesion glycolysis (TLG), apparent diffusion coefficient (ADC)
and T2* value were assessed in the same lesions. Up to 5 liver metastases per patient
were analyzed. Outcome measures were progression free survival (PFS), overall survival
(OS) and size response.
Results
Pretreatment, high SUVmax, high TLG, low ADC and high T2* were associated with a
shorter OS. Low pretreatment ADC value was associated with shorter PFS. After 1 week a
significant drop in SUVmax and rise in ADC were observed. The drop in SUV was correlated
with the rise in ADC (r=-0.58, p=0.002). Neither change in ADC nor in SUV was predictive of
PFS or OS. T2* did not significantly change after start of treatment.
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Conclusion
Pretreatment SUVmax, TLG, ADC, and T2* values in colorectal liver metastases are predic-
tive of patient outcome. Despite sensitivity of DWI and 18F-FDG PET for early treatment ef-
fects, change in these parameters was not predictive of long term outcome.
Introduction
The liver is the most frequently affected organ in disseminated colorectal cancer and most pa-
tients with metastatic disease rely on palliative systemic treatment [1]. Depending on the
schedule, response is commonly evaluated 8–9 weeks after start of treatment. Currently, re-
sponse to treatment is monitored by size response evaluation according to the RECIST criteria
[2]. A reliable tool that predicts response early after start of therapy is desirable, as this would
prevent unnecessary toxicity and costs.
Size response evaluation may be a suboptimal method to assess efficacy of targeted thera-
pies, since necrosis or fibrosis without reduction in tumor size may occur [3,4]. The outcome
of palliative systemic therapy has improved in recent years by the addition of targeted agents to
cytotoxic treatment. The addition of bevacizumab, a monoclonal antibody which targets the
vascular endothelial growth factor has resulted in significant benefits in progression free sur-
vival and overall survival [5].
Several functional imaging techniques have shown potential for prediction of response as
well as early response monitoring. In a systematic review, the role of 18F-FDG PET in treatment
response prediction and monitoring in advanced stage colorectal cancer was evaluated. Four
out of five studies showed changes in standardized uptake values (SUV) of 18F-FDG PET after
start of systemic treatment [6] and two of these four studies showed a correlation with long
term outcome [7,8]. In the palliative setting, metabolic response after one cycle of chemothera-
py was a stronger predictor for survival than RECIST evaluation after 3 cycles of chemotherapy
[9]. However, combined with other functional imaging techniques 18F-FDG-PET might be an
earlier and stronger predictor of response to therapy.
Diffusion weighted imaging (DWI) is another promising functional imaging tool for tissue
characterization, pretreatment response prediction and response evaluation in cancer [10,11].
From the diffusion weighted MR images an apparent diffusion coefficient (ADC) can be calcu-
lated, which is a measure for the mobility of water. The ADC is inversely correlated to the cell
density, since cellular membranes inhibit water movement [12]. Changes in ADC may precede
changes in tumor size, since early after start of treatment changes in cellularity and necrosis
may already occur. It has been demonstrated that ADC increased within days after chemother-
apy in colorectal cancer metastases [13,14]. These studies investigated the correlation between
ADC change and response in metastases. However, to be implemented in clinic, changes in
ADC should predict response or (progression free) survival in the patient.
Vascular changes induced by bevacizumab and chemotherapeutic treatment may also be in-
dicative of response. Furthermore, vascular status by itself may predict response, since hypoxia
and vascular supply of the chemotherapy influence treatment efficacy. T2 MRI, also called in-
trinsic susceptibility-weighted MRI or BOLD, is investigated as an alternative to (dynamic)
contrast enhanced imaging [15,16]. The transverse relaxation time, T2, is dependent on mag-
netic field inhomogeneity and is therefore significantly affected by the presence of paramagnet-
ic deoxyhemoglobin. The higher the deoxyhemoglobin concentration, the lower the T2 value
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[17]. To our knowledge, thus far no studies using T2 for response prediction of metastatic co-
lorectal cancer have been published.
The aim of this prospective study was to assess the predictive value of 18F-FDG PET, DWI
and T2 MRI for response to first line chemotherapy and outcome in advanced stage colorectal
cancer patients.
Material and methods
Patients
Between August 2009 and September 2012 patients of 18 years and older with histologically
confirmed colorectal cancer and non-resectable colorectal liver metastases starting first line
palliative or neoadjuvant chemotherapy were approached for participation in this study. Exclu-
sion criteria were: Karnofsky performance status<70, (adjuvant) chemotherapy<6 months
before study participation, renal function impairment (MDRD<60 ml/min/1.73 m2) or preg-
nancy. Specific contra-indications for 18F-FDG PET (including diabetes mellitus) or MRI only
excluded patients for either the PET or MRI part of the study protocol. The study was approved
by the medical ethics committee (Commissie Mensgebonden Onderzoek regio Arnhem-
Nijmegen: approval number: 2008/194). All patients provided written informed consent before
entering the study.
Imaging methods
Before start of chemotherapy 18F-FDG PET, contrast CT and MRI were performed. These
scans were performed median 5 days before start of treatment. One week after start of chemo-
therapy (range 6–8 days), 18F-FDG PET and MRI were repeated. After 3 cycles of chemothera-
py an 18F-FDG PET and contrast CT were performed to assess treatment response.
PET CT-scans were performed on a PET/CT scanner: a Biograph Duo (Siemens Medical
Solutions USA, Inc., Knoxville, TN, USA) for the first 26 patients and a Biograph mCT PET/
CT scanner for the 13 most recently enrolled patients. Both PET/CT-scanners were accredited
by the EANM-EARL QA/QC program for quantitative PET [18]. Images of the Biograph Duo
scanner were reconstructed using the 4 iterations/16 subsets (4i/16s) OSEM-2D reconstruction
algorithm, smoothed with a 5-mm FWHMGaussian filter. Images of the Biograph mCT scan-
ner were reconstructed using TrueX, time of flight and the 3i/21s reconstruction algorithm,
smoothed with an 8-mm FWHMGaussian filter. All PET scans were corrected with a low dose
CT for attenuation correction [19].
Contrast enhanced CT using ioversol (125ml Optiray 350) was performed. Scanning param-
eters for contrast-enhanced CT imaging were care dose referenced at 80 mAs for the thorax
and 130mAs for the abdomen, 110 kV, rotation time 0.8s, slice 3 mm, slice collimation 2.5mm,
feed/rotation 10mm for thorax and 6.3mm for the abdomen on the Biograph duo. A delay of
40s after injection of ioversol was applied for thorax imaging and a delay of 10s was set to auto-
matically shift to the abdominal imaging. The scanning parameters for CT on the Biograph
mCT were set as follows: 200 mAs, 120 kV, pitch 1.2, slice 1 mm, delay of 40s after contrast in-
jection and bolus tracking.
DWI and gradient echo measurements to obtain ADC and T2 values were performed on a
1.5T MR system (Magnetom Avanto, Siemens Medical Solutions, Erlangen, Germany) using a
body coil for excitation and a body matrix coil combined with spine matrix coil for signal re-
ception. DWI was performed with an EPI sequence and diffusion weighted images were ob-
tained in three orthogonal directions with b-values of 50, 300, and 600 s/mm2. A 2D-
Prospective Acquisition CorrEction navigator triggering was used to avoid respiratory motion
artifacts. Parallel imaging was combined with Generalized Autocalibrating Partially Parallel
Multimodality Imaging to Predict Response in Colorectal Cancer
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Acquisition and an acceleration factor of 2. Spectrally Adiabatic Inversion Recovery was in-
cluded to suppress the fat signal. Other scan parameters were as follows: TR 2000 ms; TE 82
ms; 30 transversal slices of 6.0 mm thickness separated by 1.2 mm; field of view 400x400 mm;
matrix size 192x192; bandwidth 1736 Hz/px; 3 averages; anterior-posterior phase
encoding direction.
To obtain T2 images a spoiled gradient-recalled echo, FLASH 2D, sequence was employed.
Each slice was obtained with multiple TE values (4.76, 9.53, 14.29, 19.06, 23.82, 28.58, 33.35,
38.11, 42.88, 47.64, 52.40 ms) and a TR of 225 ms. Other parameters were as follows: flip angle
25 degrees; field of view 400x400mm; slice thickness 6.0 mm; matrix size 128x128. Parallel ac-
quisition (GRAPPA) with an acceleration factor of 2 was used. Patients continued normal
breathing during the T2 scans.
Image analysis
The maximum and mean SUV (SUVmax and SUVmean) of the liver lesions with a maximum of
5 liver lesions per patient were assessed by applying a variable threshold delineation method
based on the signal-to-background ratio [20]. The liver lesions were selected based on good vis-
ible separation from other metastases and the right kidney on the PET images. The SUV was
corrected for total body weight. The adaptive threshold was calculated with the formula: thresh-
old = SUVbackground+0.41*(SUVmax-SUVbackground)[21].
All tumors were delineated using Inveon Research Workplace (IRW 3.0, Siemens Medical
Solutions, USA). A volume weighted average of the SUVmax over the assessed liver lesions was
calculated to have one average SUVmax for each patient. A total lesion glycolysis (TLG) was cal-
culated by multiplying the metabolic volume with the SUVmean for each metastasis. The sum of
the total lesion glycolysis (TLG) of the assessed tumors was calculated, to have one TLG value
per patient.
The ADC images were calculated automatically by the Syngo VB17 scanner software using
a noise level of 10. ROI’s were manually drawn on the diffusion weighted b = 50s/mm2 images
for optimal tumor-background contrast and were drawn around the entire metastasis (on all
slices). ROI’s were drawn around the same lesions as delineated on the PET scans. Inveon Re-
search Workplace overlays the ADC map on diffusion weighted b = 50s/mm2 image. The
mean ADC value in each metastasis was calculated.
T2 maps were generated using in-house built software based on Matlab (MathWorks, Na-
tick, MA, USA). The echo time data was fitted pixel by pixel to a mono-exponential curve.
ROIs drawn on diffusion weighted b = 50s/mm2 image were copied on the T2 map, to calcu-
late the mean T2 values. Baseline images and the images one week after start of treatment
were analyzed by before the outcome after 3 cycles was evaluated. To evaluate CT response, the
maximum lesion diameters after 3 and 6 cycles were compared to lesion size before start
of treatment.
Statistics
The following outcomes are indicative of the prognostic performance that can be demonstrated
with a power of approximately 80% and an overall alpha of 0.05 for different assumptions re-
garding the hazard ratio (HR) and standard deviation (SD) of the imaging parameter. In case
of high prognostic performance (HR = 0.8) of the imaging parameter, the standard deviation
needs to be at least 2, for 30 patients per group to be sufficient. For a HR of 0.90, 30 patients
per group are sufficient if SD is at least 4.25, whereas 40 patients are required to demonstrate
this association with an SD of 3.75. If the prognostic performance is even poorer (HR 0.95), 40
patients are sufficient if the SD is at least 7.5 and 60 if SD is 6. In total, 39 patients were enrolled
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in our study. Therefore, this study can demonstrate the prognostic value of an imaging parame-
ter, if the imaging parameter has a high prognostic performance.
All data acquired were imported in SPSS 20.0 (IBM SPSS Statistic, SPSS Inc., IBM, Chicago,
IL). To assess the predictive value of the pretreatment SUVmax, TLG, ADC and T2 measure-
ment to progression free and overall survival a Cox proportional regression analysis was used.
A multivariate Cox proportional regression analysis was used to assess predictive value of com-
bined parameters. Given the limited number of patients in this study, no multivariate analysis
to correct for (other) prognostic parameters was performed. Progression free survival was de-
fined as the time from start of therapy to disease progression on CT (defined according to
RECIST criteria) or death by any cause. Overall survival was defined as time from start of treat-
ment to death by any cause.
A paired sample T-test was performed to assess whether the measured SUV, T2 and ADC
one week after start of therapy significantly differed from the values before start of therapy.
Cox regression analysis was performed to assess the predictive value for PFS and OS, if the pa-
rameters showed a statistically significant change after a week.
Furthermore, we assessed the correlation between the pretreatment values and early changes
on PET and MRI with the changes on CT after 3 cycles of chemotherapy in a lesion-by-lesion
and patient-by-patient analysis.
Results
Patients
Thirty-nine patients participated in the study, 28 males and 11 females (mean age 62 years,
range 29–77 years). In total, 154 liver metastases were assessed. Patient characteristics are sum-
marized in Table 1. Two patients underwent MRI only. In two patients only an 18F-FDG PET/
CT was performed. The first follow-up scan (one week after start of treatment) was not com-
pleted by eight patients. Side effects of chemotherapy was the main reason for protocol devia-
tions. The final follow-up scans (after 3 treatment cycles) were not completed by 7 patients,
Table 2. Median follow-up was 65.5 weeks. After three cycles 43.6% (N = 17) of the patients
Table 1. Characteristics of participating patients.
Patient characteristics N = 39
Sex 71.8% male (N = 28)
28.2% female (N = 11)
Mean age 62 years (range 29–77)
Localization primary tumor 41.0% Right hemicolon (N = 16)
28.2% Left hemicolon, including sigmoid (N = 11)
23.1% Rectal cancer (N = 9)
7.7% Unknown location in colon (N = 3)
Treatment CAPOX+ bevacizumab (N = 32)
Capecitabine+ bevacizumab (N = 4)
CAPOX (N = 1)
UFT (N = 1)
FOLFOX with hyperthermia (N = 1)
Intention of treatment Neoadjuvant (N = 5)
Palliative (N = 35
CAPOX = capecitabine and oxaliplatin; UFT = tegafur-uracil; FOLFOX = ﬂuorouracil and oxaliplatin
doi:10.1371/journal.pone.0120823.t001
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showed partial response, 41.0% (N = 18) of the patients had stable disease and 12.8% (N = 5) of
the patients died or had severe progression clinically.
Predictive value of pretreatment 18F-FDG PET and MRI parameters
An example of a pretreatment 18F-FDG PET, DWI, ADC map and T2 image of a patient with
multiple liver metastases is shown in Fig. 1. In general, high uptake of FDG was visible in the
liver metastases on the PET-images. On the ADC-map, there was a dark signal (low ADC) in
the rim of all tumors and high signal in the centre of most tumors, indicating central necrosis.
There was little contrast between liver and tumor on the T2-map.
The average SUVmax in the liver lesions was 11.3 g/cm3 (range 5.8–20.5 g/cm3) and the
mean sum of the TLG in the assessed liver lesions was 1084g (range 12.8-4845g). The SUVmax
value was not a significant predictor of PFS, but was predictive of OS. Each 1.0 increase in
SUVmax was associated with a 1.125 higher risk of death (95% CI 1.020–1.241, p = 0.02). Al-
though TLG was not predictive of PFS, it did show predictive value for OS: each 100g increase
in pretreatment TLG value was associated with a 1.047 increased hazard of dying (95% BI
1.010–1.085, p = 0.01).
The average pretreatment ADC value was 1.21 10–3 mm2/s and the average pretreatment
T2 value was 30.2 ms. The pretreatment ADC value was a significant predictor of both PFS
and OS: a 0.1 10–3 mm2/s higher pretreatment ADC value provided a hazard ratio of 0.749
for progression (95% CI 0.561–1.000, p = 0.05) and a decreased risk of dying (HR 0.667, 95%
CI 0.466–0.955, p = 0.03). Kaplan Meier survival plots for the patients with higher and lower
than median ADC are shown in Fig. 2.
Pretreatment T2 value was a significant predictor for OS, but not for PFS. A 1 ms higher
average T2 time was associated with an increased risk of dying (HR 1.118, 95% CI 1.023–
1.222, p = 0.01).
Combining the pretreatment ADC values and SUVmax in a multivariate model showed a
higher predictive value for survival, p<0.01. Adding T2 or TLG parameters did not increase
the predictive value of the model.
Pretreatment SUVmax, ADC and T2 were not correlated to the size change on CT after
three cycles of chemotherapy, neither in the patient-by-patient analysis nor in the lesion-by-
lesion analysis.
Predictive value of early changes in 18F-FDG PET and MRI parameters
SUVmax significantly decreased one week after start of treatment (SUVmax: 11.3 to 6.3,
p<0.01). SUVmax decreased on average with 18.0% ±19.1% (range 66.1% decrease-14.8% in-
crease).TLG decreased on average 19% ±35.0% after one week of treatment (1084 to 726,
Table 2. Average 18F-FDG PET, MRI and CT parameters at pretreatment, one week after start of therapy and after 3 cycles of therapy.
Pretreatment Average (SD) 1 week Average (SD) 3 cycles Average (SD)
FDG PET N = 37 N = 30 N = 29
SUVmax (g/cm3) 11.4 (4.7) 8.8 (3.7) 5.0 (3.3)
TLG (g) 1084 (1244) 726 (1145) 144 (212)
MRI N = 36 N = 29
DWI (ADC) 1.21 (0.17) 1.27 (0.20)
T2* (ms) 30.2 (7.0) 26.7 (8.1)
CT (RECIST) N = 39 N = 31
Sum of diameters (mm) 153 (90) 104 (74)
doi:10.1371/journal.pone.0120823.t002
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p = 0.07). The ADC values significantly increased after one week of treatment from 1.20 to 1.27
10–3 mm2/s (p = 0.01). The average increase was 0.0710–3 mm2/s ± 0.1310–3 mm2/s. The
T2 values were on average 30.2ms before treatment and 26.7ms one week after start of treat-
ment. This was not a significant decrease (p = 0.17).
The change in ADC value was inversely correlated to the change in SUVmax, r = -0.58,
p<0.01, Fig. 3. No correlation with changes in T2 was observed. The degree of change in SUV-
max, TLG and ADC were not predictive of either PFS or OS. Also combined changes in SUVmax,
TLG and ADC did not predict PFS or OS.
Furthermore, the change in SUVmax, TLG and ADC after one week did not correlate to size
change on CT after 3 cycles in a lesion by lesion analyses or patient-by-patient analysis. As
shown in Fig. 4, there is no difference between CT responders and non responders in change in
SUVmax or ADC. Of note, in only 23 metastases an increase in SUV after one week of treatment
was observed, of which 16 metastases had a reduced diameter after 3 cycles.
Fig 1. Typical images acquired with FDG PET, DWI and T2* of a patient with multiple liver metastases . One liver metastasis is delineated with a blue
line on A) FDG-PET/CT B) a diffusion weighted image (b-value 50 s/mm2), C) ADC-map and D) T2*-map.
doi:10.1371/journal.pone.0120823.g001
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Discussion
Pretreatment 18F-FDG PET and MRI parameters
Combining the pretreatment ADC values and SUVmax in a multivariate model showed a higher
predictive value for survival. Also, a correlation between SUVmax and survival was observed.
This is in line with previous studies, performed in patients with both primary resectable and
irresectable colorectal liver metastases, in which significantly higher pretreatment SUV was as-
sociated with poorer outcome [7,22].
Fig 2. Kaplan Meier Survival curve for a higher (green) or lower (blue) thanmean ADC value (1.21 mm2/s) at pretreatment, showing a significant
difference in overall survival (p = 0.022) and progression free survival (p = 0.001).
doi:10.1371/journal.pone.0120823.g002
Fig 3. Regression analysis of the changes in SUVmax on differences in ADC one week after start of
treatment (r = -0.58, p = 0.002). The fit line (red) and 95% confidence interval (black) are shown.
doi:10.1371/journal.pone.0120823.g003
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In this study, lower pretreatment ADC values predicted poorer outcome, which may be related
to the association between ADC values and histological grade. In breast and prostate cancer lower
ADC values were correlated with higher histological grade and higher Gleason score [23–25]. In
colorectal cancer, a higher histological grade is correlated with an adverse outcome [26,27]
A low T2 value, indicating higher concentration of deoxyhemoglobin, was favorable for
longer OS, but did not correlate with PFS. However, the deoxyhemoglobin is not only
Fig 4. Boxplots showing the change in SUVmax and ADC in patients with partial response, minor
response, stable disease and in patient unable to perform the scan after 3 cycles due to clinical
progression or death. There was no relation between response and changes in SUVmax or ADC.
doi:10.1371/journal.pone.0120823.g004
Multimodality Imaging to Predict Response in Colorectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0120823 April 1, 2015 9 / 13
dependent on hypoxia. In very poor vascular supply and necrotic areas, there may be also very
little deoxyhemoglobin present.
Early changes in 18F-FDG PET and MRI parameters
Both 18F-FDG PET and DWI showed therapy induced changes one week after start of treat-
ment. The changes in 18F-FDG PET and DWI were correlated, suggesting an association be-
tween treatment effects leading to decreased cellular density and metabolic response.
Unfortunately, the measured treatment effects were not predictive of survival or CT-re-
sponse. The lack of (strong) relation between changes in 18F-FDG PET and MRI parameters
and treatment outcome can be attributed to several factors. In contrast to comparable previous
studies, bevacizumab was part of the standard treatment regimen in the present study. Antian-
giogenic treatments, such as bevacizumab, may alter the distribution of intravenously injected
tracers or contrast agents in the tumor [28]. Decrease in SUV might therefore, in part, reflect
alterations in tumor blood supply, rather than metabolic changes. This might obscure the asso-
ciation between metabolic response and treatment outcome. The use of a variable threshold to
delineate the tumor on 18F-FDG-PET may have resulted in an underestimation of the effect of
treatment on TLG, since SUVmax decreased as an effect to treatment and therefore the thresh-
old was lower for the second scan. However, the use of a fixed threshold is also problematic
due to high background activity in liver tissue.
DWI and T2 are not dependent on administration of intravenous contrast agents. Howev-
er, the observed increase in ADC and reduction in T2 may be a reflection of therapy induced
necrosis, related to a favorable outcome, as well as to bevacizumab induced reduction in vascu-
larization and hypoxia, related to therapy resistance and a dismal outcome. Thus, the relation
between outcome and changes in DWI and T2 are obscured by differential effects on the
tumor. T2 did not significantly alter after start of treatment. Therefore, this parameter may be
less suitable as a predictor of response to therapy.
Finally, the interval between start of treatment and the first evaluation may be of crucial im-
portance for response monitoring with 18F-FDG PET and ADC. An interval of one week after
start of targeted therapy containing treatment might be too short for 18F-FDG PET. 1–2 weeks
after start of treatment a flare-up phenomenon has been described, defined by an initial rise in
metabolic activity in lesions that would respond later on [29]. This phenomenon might also in-
terfere with the measured parameters.
Conversely, changes in ADC cannot only precede changes in tumor size, but may even dis-
appear after a certain time due to activated repair mechanisms [30]. In a previous study an in-
crease in ADC in colorectal and gastric liver metastases (of 23 patients) was described after 3
and 7 days of treatment. However, only a weak correlation between change in ADC on day 3
and final change in size could be established, whereas no significant correlation between
changes at day 7 and final lesion size was observed [13]. Therefore, it might be more effective
to measure ADC at a shorter time interval after start of treatment. Finally, we can only specu-
late on the optimal interval for early response prediction using T2 in the present study. In a
breast cancer study after 2 cycles of chemotherapy, however, a significant increase in T2 was
observed [31], suggesting that longer time intervals may benefit.
Study limitations
Due the limited number of patients we can conclude that there is no high prognostic value in
the early changes in PET-values and ADC after start of treatment, but weaker relations (with
lower prognostic value) could be easily missed.
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The patients with the poorest treatment outcome could not complete all scans which further
limits correlation with changes in size after 3 cycles. The use of two different PET-CT scanners
should not have influenced the predictive value of the pretreatment SUV and TLG measure-
ments as both scanners were EANM-EARL accredited for quantitative PET.
Conclusion
Pretreatment TLG values, ADC and T2 in colorectal liver metastases are predictive of patient
survival. In the future, this could provide the opportunity to select patients who could benefit
from chemotherapy prior to start of treatment. Early effects after one week of treatment with
chemo- and targeted therapy can be measured with 18F-FDG PET and DWI, however, these ef-
fects were not predictive of long term outcome in this study.
Supporting Information
S1 Dataset. This excel file contains the (anonymous) raw data needed to reproduce our re-
sults. All patients were given one study number and have scan data in up to three time points:
before chemotherapy (1), one week after chemotherapy (2) and after 3 cycles (3). Average T2
of all assessed lesions (in ms) is given, as is the difference in T2. The mean ADC per assessed
tumor and the average ADC of all assessed tumors is given (in 10–6 mm/s2). The SUVmax per
tumor, the volume-weighted average SUVmax and the total TLG are given. The maximum di-
ameter (in mm) per assessed lesion is reported, as is the calculated response on CT. Further-
more, it reports whether patients had a metastasectomy after study participation (2) of not (1),
were progressive (1) during follow up or had still a response (2), died during follow-up (1) or
were still alive (2) at the end of follow up. Progression free survival and overall survival are re-
ported in weeks.
(XLSX)
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